Paper Details

  1. Home
  2. Paper Details

Dasatinib.

Author: HochhausAndreas, LindauerMarkus

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Dasatinib is an oral tyrosine kinase inhibitor effective for chronic myeloid leukemia (CML) and Philadelphia-chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It causes deeper and faster molecular remissions in CML compared to imatinib, but side effects like cytopenias and pleural effusions are common.
Paper Details　
Original Abstract of the Article :
Dasatinib is an oral available short-acting inhibitor of multiple tyrosine kinases. It was designed to inhibit ABL and SRC, but also has activity in multiple other kinases, including c-KIT, PDGFR-α, PDGFR-β, and ephrin receptor kinases. Dasatinib is a very potent inhibitor of BCR-ABL and an effectiv...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/978-3-319-91439-8_2

データ提供：米国国立医学図書館（NLM）

Dasatinib: A Potent Inhibitor for Chronic Myeloid Leukemia

The field of [chronic myeloid leukemia (CML)] treatment has witnessed remarkable advancements, and this research explores the role of [dasatinib], a potent [tyrosine kinase inhibitor], in managing this complex disease. The authors provide a comprehensive overview of the [preclinical and clinical] evidence supporting the use of [dasatinib] for [CML], highlighting its effectiveness in inducing [molecular remissions] and its potential as a valuable treatment option for patients with [CML].

A New Oasis in the Desert of CML Treatment

The research highlights the significant efficacy of [dasatinib] in treating [CML], particularly in patients who have developed [resistance] or [intolerance] to [imatinib]. The authors emphasize the importance of [individualized treatment plans] based on [patient characteristics] and [disease stage] to maximize the therapeutic benefit of [dasatinib].

Navigating the Sands of CML Treatment

The journey to conquer [CML] is a long and challenging one, requiring a multifaceted approach. This research shines a light on the potential of [dasatinib] as a powerful weapon in this fight, offering hope for patients who have previously struggled with [CML]. It’s a testament to the progress made in [cancer research], highlighting the importance of developing new and effective treatments to address the unique challenges of this complex disease.

Dr.Camel's Conclusion

This research offers a beacon of hope for patients with [CML]. It’s a testament to the relentless pursuit of new and effective treatments for this challenging disease. By continuing to explore the potential of [dasatinib] and other [tyrosine kinase inhibitors], we can provide patients with more options and potentially improve their chances of achieving long-term remission and a better quality of life.

Date :
  1. Date Completed 2019-05-20
  2. Date Revised 2019-05-20
Further Info :

Pubmed ID

30069624

DOI: Digital Object Identifier

10.1007/978-3-319-91439-8_2

Related Literature

Article Analysis
・Side Effects of dasatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.